Subtopic Deep Dive
CAR-T Cell Therapy for Hematologic Malignancies
Research Guide
What is CAR-T Cell Therapy for Hematologic Malignancies?
CAR-T cell therapy for hematologic malignancies applies chimeric antigen receptor-modified T cells targeting CD19 to treat relapsed/refractory leukemias and lymphomas.
Clinical trials demonstrate high response rates in B-cell acute lymphoblastic leukemia (ALL) and large B-cell lymphoma with products like CTL019 and axicabtagene ciloleucel (axi-cel). Durable remissions occur in 40-80% of patients, though cytokine release syndrome (CRS) and neurotoxicity require management (Neelapu et al., 2017; 5606 citations; Maude et al., 2014; 5256 citations). Over 20 pivotal trials since 2014 validate efficacy in blood cancers.
Why It Matters
CAR-T therapies achieve complete remissions in chemotherapy-refractory B-cell malignancies, with axi-cel yielding 83% overall response and 58% complete response in large B-cell lymphoma (Neelapu et al., 2017). In ALL, CTL019 induced 93% remission rates, including post-stem cell transplant failures (Maude et al., 2014). Ide-cel CAR-T targets BCMA in multiple myeloma, achieving MRD-negativity in 26% of relapsed patients (Munshi et al., 2021). Consensus grading scales standardize CRS and neurotoxicity management across trials (Lee et al., 2018). These outcomes extend survival where prior therapies failed, guiding FDA approvals like Kymriah and Yescarta.
Key Research Challenges
Cytokine Release Syndrome Management
CRS occurs in most CAR-T patients, with grade 3+ events in 13-40% requiring tocilizumab (Neelapu et al., 2017). Neurotoxicity follows in 20-60% of cases, graded by ASTCT consensus (Lee et al., 2018). Balancing efficacy and safety demands standardized protocols.
Antigen Escape and Relapse
CD19-negative relapses limit durability in 10-30% of ALL responders (Maude et al., 2014). Dual-target CARs or consolidation strategies are explored (Sterner and Sterner, 2021). Tumor microenvironment resistance persists despite high initial responses.
Manufacturing and Toxicity Scaling
Apheresis failures and production delays affect 5-10% of patients (Neelapu et al., 2017). Hematologic toxicities grade 3+ in 90% post-ide-cel infusion (Munshi et al., 2021). Off-the-shelf allogeneic CAR-T aims to address logistics (Sterner and Sterner, 2021).
Essential Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · 2017 · New England Journal of Medicine · 5.6K citations
In this multicenter study, patients with refractory large B-cell lymphoma who received CAR T-cell therapy with axi-cel had high levels of durable response, with a safety profile that included myelo...
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude, Noelle V. Frey, Pamela A. Shaw et al. · 2014 · New England Journal of Medicine · 5.3K citations
Chimeric antigen receptor-modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL. CTL019 was associated with a high remission rate, even among patients for whom ...
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Alex D. Waldman, Jill M. Fritz, Michael J. Lenardo · 2020 · Nature reviews. Immunology · 3.9K citations
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee, Bianca Santomasso, Frederick L. Locke et al. · 2018 · Biology of Blood and Marrow Transplantation · 3.1K citations
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
Yuanyuan Zhang, Zemin Zhang · 2020 · Cellular and Molecular Immunology · 2.6K citations
Abstract Immunotherapy has revolutionized cancer treatment and rejuvenated the field of tumor immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) and immune checkpoin...
CAR-T cell therapy: current limitations and potential strategies
Robert C. Sterner, Rosalie M. Sterner · 2021 · Blood Cancer Journal · 2.5K citations
Abstract Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certai...
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
Sattva S. Neelapu, Sudhakar Tummala, Partow Kebriaei et al. · 2017 · Nature Reviews Clinical Oncology · 2.3K citations
Reading Guide
Foundational Papers
Start with Maude et al. (2014; 5256 cites) for CD19 CAR-T in ALL remissions and Kochenderfer et al. (2014; 1593 cites) for anti-CD19 CAR in B-cell lymphomas to grasp early efficacy proofs.
Recent Advances
Study Neelapu et al. (2017; axi-cel), Munshi et al. (2021; ide-cel myeloma), and Sterner (2021; limitations) for current toxicities and strategies.
Core Methods
CD19/BCMA-targeting 2nd/3rd-gen CARs with 4-1BB/CD28 costimulation; fludarabine/cyclophosphamide lymphodepletion; ASTCT CRS grading (Lee et al., 2018).
How PapersFlow Helps You Research CAR-T Cell Therapy for Hematologic Malignancies
Discover & Search
Research Agent uses searchPapers('CAR-T hematologic malignancies CD19 response rates') to retrieve Neelapu et al. (2017) as top hit with 5606 citations, then citationGraph reveals 500+ forward citations on axi-cel outcomes and findSimilarPapers uncovers Maude et al. (2014) for ALL parallels. exaSearch scans 250M+ OpenAlex papers for multicenter trial meta-analyses.
Analyze & Verify
Analysis Agent applies readPaperContent on Neelapu et al. (2017) to extract 83% ORR data, verifyResponse with CoVe cross-checks remission rates against Maude et al. (2014), and runPythonAnalysis computes survival curves from Kaplan-Meier appendices using pandas/matplotlib. GRADE grading scores trial evidence as high for refractory lymphoma endpoints.
Synthesize & Write
Synthesis Agent detects gaps like antigen escape post-CD19 CAR-T via contradiction flagging across Sterner (2021) and Maude (2014), then Writing Agent uses latexEditText for methods sections, latexSyncCitations to integrate 20+ refs, and latexCompile for trial comparison tables. exportMermaid generates CRS grading flowcharts from Lee et al. (2018).
Use Cases
"Extract and plot survival data from axi-cel lymphoma trial appendices"
Research Agent → searchPapers('Neelapu axi-cel') → Analysis Agent → readPaperContent + runPythonAnalysis(pandas parse Kaplan-Meier, matplotlib survival plot) → researcher gets CSV/PNG of 58% CR rate curves.
"Draft LaTeX review comparing CD19 CAR-T in ALL vs lymphoma"
Synthesis Agent → gap detection(Maude 2014 vs Neelapu 2017) → Writing Agent → latexEditText(intro) → latexSyncCitations(10 papers) → latexCompile → researcher gets PDF with response rate table and citations.
"Find GitHub repos analyzing CAR-T clinical datasets"
Research Agent → searchPapers('CAR-T hematologic trial data') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets repo with R scripts for CRS incidence stats from Lee et al. (2018)-inspired models.
Automated Workflows
Deep Research workflow runs searchPapers on 'CAR-T hematologic malignancies' → citationGraph(Neelapu cluster) → DeepScan(7-step verify on 50+ papers) → structured report with GRADE-scored response rates. Theorizer generates hypotheses on CRS prevention from Lee (2018) + Sterner (2021) patterns. DeepScan applies CoVe chain to validate relapse mechanisms across Maude/Munshi trials.
Frequently Asked Questions
What defines CAR-T for hematologic malignancies?
Genetically modified T cells expressing CD19-targeting CARs treat B-cell ALL, lymphomas, and myeloma (Maude et al., 2014; Neelapu et al., 2017).
What are main methods in CAR-T trials?
Lymphodepletion followed by autologous CAR-T infusion; endpoints include ORR, CR, and EFS with CRS grading (Lee et al., 2018; Munshi et al., 2021).
What are key papers?
Neelapu et al. (2017; axi-cel lymphoma; 5606 cites), Maude et al. (2014; CTL019 ALL; 5256 cites), Munshi et al. (2021; ide-cel myeloma).
What open problems exist?
Relapse via antigen loss, CRS/neurotoxicity mitigation, and scaling to solid tumors (Sterner and Sterner, 2021).
Research CAR-T cell therapy research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching CAR-T Cell Therapy for Hematologic Malignancies with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the CAR-T cell therapy research Research Guide